VIAL

Peptide Therapy

45 verified Peptides providers in Vial’s directory.

What are Peptides?

Peptide therapy occupies a unique position in optimization medicine, bouncing between mainstream clinical practice and a grey market where sourcing, physician oversight, and compounding standards vary enormously. BPC-157, TB-500, CJC-1295, Ipamorelin, and others are prescribed by licensed physicians through legitimate compounding pharmacies and sold as research chemicals through unregulated online vendors, often under identical branding. The difference between a legitimate peptide protocol and a grey-market one is not visible from a provider's website. Vial surfaces physician licensing, pharmacy relationships, and federal compliance records to make that distinction clear.

Top Peptides providers in Vial’s directory

Ranked by Trust Score. Showing 10 of 45. See all Peptides providers →

How Vial evaluates Peptides providers

Vial verifies peptide therapy providers across six dimensions: regulatory standing, clinical transparency, pharmacy and fulfillment, commercial transparency, operating history, and industry standing. For peptide therapy specifically, we weight pharmacy partnership disclosure heavily because most peptides are compounded — knowing who makes them is the safety signal that matters most.

Read the full methodology →

Peptides compounds

Compounds commonly used in Peptides protocols. See all compounds →

RecoveryPreclinical
BPC-157
A synthetic 15-amino-acid peptide derived from human gastric juice proteins, BPC-157 (Body Protection Compound-157) demonstrates cytoprotective and regenerative properties in preclinical studies. Research in animal models suggests it may accelerate healing of tendons, ligaments, muscle, and gastrointestinal tissue through mechanisms involving angiogenesis, growth factor modulation, and nitric oxide pathway regulation. While extensively studied in rodent injury models, human clinical trial data remains limited, and the compound is not currently approved for therapeutic use by major regulatory agencies.
Grey Area→
PeptideClinical Trials
CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH), this 30-amino acid peptide is modified with a drug affinity complex (DAC) that extends its half-life by binding to serum albumin. It stimulates pulsatile growth hormone secretion from the anterior pituitary by activating GHRH receptors. The compound has been investigated in clinical research for growth hormone deficiency and conditions associated with impaired GH/IGF-1 axis function.
Legal Compounded→
PeptideClinical Trials
Ipamorelin
A synthetic pentapeptide growth hormone secretagogue, ipamorelin selectively stimulates pituitary release of growth hormone by mimicking ghrelin and binding to the growth hormone secretagogue receptor (GHS-R). Unlike earlier secretagogues, it demonstrates high selectivity for GH release with minimal effect on cortisol, prolactin, or appetite-regulating hormones. Research applications have focused on its potential use in growth hormone deficiency, age-related muscle loss, and bone metabolism studies.
Legal Compounded→
PeptideClinical Trials
Sermorelin
A synthetic analog of growth hormone-releasing hormone (GHRH), this 29-amino acid peptide stimulates the pituitary gland to produce and secrete endogenous growth hormone through binding to GHRH receptors. It functions by mimicking the N-terminal bioactive portion of native GHRH, promoting pulsatile GH release while preserving the body's natural feedback mechanisms. Primary applications include diagnostic testing of pituitary function and therapeutic use in growth hormone deficiency.
Legal Compounded→
RecoveryPreclinical
TB-500
A synthetic peptide fragment derived from Thymosin Beta-4, this compound functions as an actin-sequestering protein that promotes cell migration, angiogenesis, and tissue repair. Its mechanism involves upregulating cell-building proteins and reducing inflammation at injury sites. Research applications have focused primarily on wound healing, cardiac tissue repair following ischemic injury, and musculoskeletal recovery in preclinical models.
Grey Area→
PeptideFDA Approved
PT-141
A synthetic cyclic heptapeptide melanocortin receptor agonist, bremelanotide (PT-141) acts primarily on MC4 receptors in the central nervous system to modulate sexual arousal pathways. The compound increases sexual desire through direct neurological mechanisms rather than peripheral vascular effects. Its primary clinical application is the treatment of hypoactive sexual desire disorder in premenopausal women.
FDA Approved→
RecoveryObservational
GHK-Cu
A naturally occurring copper-binding tripeptide found in human plasma, GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) functions as a signaling molecule that modulates gene expression related to tissue remodeling, collagen synthesis, and wound healing. Research demonstrates its capacity to stimulate fibroblast activity, promote angiogenesis, and exhibit anti-inflammatory and antioxidant properties. Primary applications include dermatological research for wound repair and skin aging, with emerging investigation into its potential roles in tissue regeneration and fibrosis modulation.
Legal Compounded→
MetabolicPreclinical
MOTS-c
A mitochondrial-derived peptide encoded by the 12S rRNA gene, MOTS-c functions as a signaling molecule that regulates metabolic homeostasis by activating AMPK and influencing glucose uptake, insulin sensitivity, and fatty acid oxidation. This peptide has demonstrated effects on cellular metabolism and exercise mimetic properties in preclinical studies. Current research focuses on its potential applications in metabolic dysfunction, age-related decline, and insulin resistance.
Grey Area→

Frequently Asked Questions

Related pillars

Longevity (overview)